Heart Stem Cell Trial Passes First Safety Test

Heart Stem Cell Trial Passes First Safety Test

The adult stem cell provider Osiris Therapeutics, Inc. announced recently that “its multi-center, human clinical stem cell trial for the treatment of patients suffering from heart attacks has successfully passed the first safety milestone of the trial. Additionally, the novel stem cell therapy was cleared by the presiding independent safety board to begin enrolling patients at higher doses of drug.”

The release goes on to say that the study involves post-heart attack treatment with adult stem cells obtained from healthy unrelated donors. The safety phase of the trials began enrolling in March, and the independent safety review board has concluded that the study proceed and a higher dose of the drug be evaluated. The drug is known as Provacel and is delivered to patients through an IV line. The stem cells then are expected to migrate to the heart.

Osiris is also enrolling patients in three other stem cell studies.